– Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types – – Five active clinical trials across four clinical programs, with data readouts for all four programs expected in 2020 – – Company to host conference call today at 4:30 p.m.

SAN DIEGO --(BUSINESS WIRE)--Aug. 5, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report

– Multiple trial initiations and data readouts expected in the next 12 months – – Company to host conference call today at 8:30 a.m. ET – SAN DIEGO --(BUSINESS WIRE)--May 14, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring,

SAN DIEGO --(BUSINESS WIRE)--May 9, 2019-- Gossamer Bio, Inc.  (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report

SAN DIEGO --(BUSINESS WIRE)--May 2, 2019-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a

SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Gossamer Bio, Inc.  (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi

SAN DIEGO --(BUSINESS WIRE)--Mar. 22, 2019-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial

SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2019-- Gossamer Bio, Inc.  (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila

SAN DIEGO --(BUSINESS WIRE)--Feb. 12, 2019-- Gossamer Bio, Inc.  (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of

SAN DIEGO --(BUSINESS WIRE)--Feb. 7, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its